The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-18 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
It is also expected that thorium-232 should be able to undergo double beta decay, which would produce uranium-232, but this has not yet been observed experimentally. All isotopes from 232U to 236U inclusive have minor cluster decay branches (less than 10−10%), and all these bar 233U, in addition to 238U, have minor spontaneous fission branches; the greatest branching ratio for spontaneous fission is about 5×10−5% for 238U, or about one in every two million decays. The shorter-lived trace isotopes 237U and 239U exclusively undergo beta decay, with respective half-lives of 6.752 days and 23.45 minutes. In total, 28 isotopes of uranium have been identified, ranging in mass number from 214 to 242, with the exception of 220. Among the uranium isotopes not found in natural samples or nuclear fuel, the longest-lived is 230U, an alpha emitter with a half-life of 20.23 days. This isotope has been considered for use in targeted alpha-particle therapy (TAT). All other isotopes have half-lives shorter than one hour, except for 231U (half-life 4.2 days) and 240U (half-life 14.1 hours). The shortest-lived known isotope is 221U, with a half-life of 660 nanoseconds, and it is expected that the hitherto unknown 220U has an even shorter half-life. The proton-rich isotopes lighter than 232U primarily undergo alpha decay, except for 229U and 231U, which decay to protactinium isotopes via positron emission and electron capture, respectively; the neutron-rich 240U, 241U, and 242U undergo beta decay to form neptunium isotopes.
== Clinical significance == Hepatokines can serve as biomarkers and are potential therapeutic targets for metabolic diseases. The liver through execretion of hepatokines regulates the whole bodies metabolism in response to stress signals. Secreted hepatokines in response to exercise induce favorable metabolic changes in fat, blood vessels, and skeletal muscle that can reduce metabolic diseases. Although substantial progress has been made in understanding disease-controlled production of hepatokines, there is still so much to discover. There is so much room for discovery. For example, "little is known about the inductive mechanism of transcriptional reprogramming, protein translation, modification, and secretion of hepatokines, particularly through the ER and Golgi, and more. The identification and functional characterization of hepatokines may provide significant insights that could help in better understanding of MetS pathogenesis.
== Outside Europe and Asia == In the New World, lead production was recorded soon after the arrival of European settlers. The earliest record dates to 1621 in the English Colony of Virginia, fourteen years after its foundation. In Australia, the first mine opened by colonists on the continent was a lead mine, in 1841. In Africa, lead mining and smelting were known in the Benue Trough and the lower Congo Basin, where lead was used for trade with Europeans, and as a currency by the 17th century, well before the scramble for Africa.
Michael Peter Epstein (born April 4, 1943), nicknamed "Super Jew", is an American former professional baseball player for the Baltimore Orioles, Washington Senators / Texas Rangers, Oakland Athletics, and California Angels of Major League Baseball (MLB).
== Role in metabolism == Sugar phosphates are major players in metabolism due to their task of storing and transferring energy. Not only ribose 5-phosphate but also fructose 6-phosphate are an intermediate of the pentose-phosphate pathway which generates nicotinamide adenine dinucleotide phosphate (NADPH) and pentoses from glucose polymers and their degradation products. The pathway is known as glycolysis where the same carbohydrates are degraded into pyruvates thus providing energy. Enzymes are catalysed for the reactions of these pathways. Some enzymes contain metal centers in their active site which is important part of the enzymes and as well as for the catalysed reaction. The phosphate group can coordinate to the metal center for example, 1,6-bisphosphatase and ADP-ribose pyrophosphatase. Phosphoglycerate and several sugar phosphates that are known intermediates of the Calvin photosynthetic carbon cycle, stimulate light-dependent carbon dioxide fixation by isolated chloroplasts. This ability is shared by certain other metabolites (e.g. glucose 1-phosphate) from which the accepted Calvin-cycle intermediates could easily be derived by known metabolic routes.
Sources: en.wikipedia.org
Linear RGD peptides suffer from low binding affinity, rapid degradation by proteases, and lack of specificity for integrin type. RGD can be cyclized, or made into a cyclic compound, via disulfide, thioether, or rigid aromatic ring linkers. This leads to an increase in binding affinity and selectivity for integrin αVβ3 relative to αIIBβ3. For example, the cyclic peptide ACDCRGDCFCG, also known as RGD4C, was shown to be 200-fold more potent than commonly used linear RGD peptides. The structural rigidity of cyclic RGD peptides improves their binding properties and prevents degradation at the highly susceptible aspartic acid residue, thereby increasing their stability. Many RGD derivative drugs and diagnostics are cyclized, including Eptifibatide, Cilengitide, CEND-1, and 18F-Galacto-RGD, and 18F-Fluciclatide-RGD.
=== Thorium-231 === 231Th has 141 neutrons. It is the decay product of uranium-235. It is found in very small amounts on the earth and has a half-life of 25.52 hours. When it decays, it emits a beta ray and forms protactinium-231, with a decay energy of 0.39 MeV.
=== Both === Amylin analogues can both reduce energy intake and increase expenditure and can usefully be combined with leptin analogues for synergistic effect. The dual amylin and calcitonin receptor agonist cagrilintide, in combination with semaglutide, was more effective than semaglutide alone in promoting weight loss in clinical trials. Glucagon receptor agonists both reduce energy intake and increase energy expenditure in humans. They can cause hyperglycemia so it is recommended to combine them with a hypoglycemic drug, such as a GLP-1 or GIP receptor agonist.
His military friend was quoted as saying that their unit was allegedly deployed to South Ossetia for the exercises, but suddenly the war broke out. On 26 August 2008, Drug dlya druga reported that one mother was told by her son on 6 August that his company would be sent to South Ossetia on 9 August. At 3 am on 8 August her son was sent to Tskhinvali, where he was wounded. On 27 August 2008, Vecherny Saransk reported that Yunir Bikkinyaev, contract soldier of 135th Regiment, stopped to answer the phone calls on 7 August and his parents were worried. He later acknowledged he did so not to frighten his family. On 28 August 2008, Gazeta Yuga published a report about Zalim Gegraev, a wounded soldier from 1st company of the peacemaking battalion, who fought in South Ossetia. Gegraev's mother said that her son had told her that he was going to Tskhinvali before the war started. She also said that he had been to South Ossetia previously and when he was there, his phone did not work. Then Zalim spoke to journalist: "We had been there to participate in military exercises for a month in those areas before this. They ended, however we were not withdrawn. Then the order came to move to Tskhinvali. On 8 August we were near the town and waited for further instructions. I didn't even think that I could see such thing..."
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.